Provided by Tiger Trade Technology Pte. Ltd.

Quince Therapeutics, Inc.

31.73
+2.378.07%
Post-market: 31.730.00000.00%19:40 EDT
Volume:138.74K
Turnover:4.63M
Market Cap:32.27M
PE:-0.35
High:37.00
Open:30.50
Low:29.84
Close:29.36
52wk High:909.98
52wk Low:15.10
Shares:1.02M
Float Shares:679.70K
Volume Ratio:4.26
T/O Rate:20.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-90.9250
EPS(LYR):-335.2669
ROE:-153.84%
ROA:-31.51%
PB:-0.91
PE(LYR):-0.09

Loading ...

Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle

Reuters
·
Aug 01

Quince Therapeutics Announces Special Shareholder Meeting

Reuters
·
Aug 01

Quince Therapeutics - Offers 15,470,099 Shares of Common Stock for Resale - SEC Filing

THOMSON REUTERS
·
Aug 01

Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)

TIPRANKS
·
Jul 31

Quince Therapeutics : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $82

THOMSON REUTERS
·
Jul 29

Quince Therapeutics Appoints Paul Yu to Chair New Pulmonary Scientific Advisory Board

Reuters
·
Jun 30

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

THOMSON REUTERS
·
Jun 30

Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts

TIPRANKS
·
Jun 27

Quince Therapeutics Amends 8-K to Correct Reverse Stock Split Description

Reuters
·
Jun 27

Quince Therapeutics files Form 3 for director, Chief Corporate Affairs Officer Brigette Roberts

Reuters
·
Jun 12

Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100

Reuters
·
Jun 12

Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million

Reuters
·
May 22

Quince Therapeutics announces LAM-001 data

TIPRANKS
·
May 18

Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed

TIPRANKS
·
May 18

Quince Therapeutics prices private placement raising up to $187 million

Reuters
·
May 18

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

Reuters
·
May 18

Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001

Reuters
·
May 18

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

THOMSON REUTERS
·
May 18

Quince Therapeutics reports Phase 2a LAM-001 gains in PH-ILD patients

Reuters
·
May 18

Quince Therapeutics - Lam-001 Generally Well Tolerated in Phase 2a Study

THOMSON REUTERS
·
May 18